Drug intelligence / Profile preview

SURF-300

Development stage: Preclinical
Lead developer: Surface Pharmaceuticals
Administration: Ophthalmic

Overview

SURF-300 is a proprietary topical eye drop formulation developed by Surface Pharmaceuticals, a spin-out company originally from Imprimis Pharmaceuticals (now Harrow Health). It is one of three drug candidates (SURF-100, SURF-200, SURF-300) in Surface Pharmaceuticals' pipeline, targeting ocular surface diseases such as dry eye disease and blepharitis. The development of SURF-300 aims for FDA approval via the 505(b)(2) pathway, leveraging the Klarity delivery vehicle technology. Clinical development for this drug candidate is being funded through Series A financing rounds.

Beyond the preview

Go deeper on SURF-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SURF-300.

Explore the full profile